NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Tango Therapeutics, Inc. TNGX
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$62.4M
▲ 48.3% vs FY2024
EPS · FY25
$-0.87
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-37.2%
Net margin · FY25
-162.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 62.4M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 163 cents on every revenue dollar this year.
Per share
USD -0.87
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-37.2%
Return on equity, FY2025
ROE
Operating margin-178.4%
Net margin-162.9%
Return on assets-28.4%
Each USD of equity lost 37 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+52.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+35.9%
+52.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.14B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 398.7M
total assets, end of FY2025
Total assetsUSD 398.7M
EquityUSD 346.2M
CashUSD 112.3M
Current ratio16.32×
Equity funds 87% of total assets.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.1
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
EPS, diluted $
−0.87
−1.19
−1.08
−1.23
−0.94
−1.63
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−37.2
−57.6
−40.5
−36.4
−30.4
−134.6
Shares out B
0.14
0.11
0.10
0.09
0.09
0.04
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
18 of 18
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed